Morgan Stanley on Axsome Therapeutics (AXSM), 'We continue to see the expected upcoming FDA action on AXS-05 as a significant catalyst for AXSM'
Tweet Send to a Friend
Morgan Stanley analyst Vikram Purohit reiterated an Equalweight rating and $27.00 price target on Axsome Therapeutics (NASDAQ: AXSM).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
